ClinicalTrials.gg
CompletedNCT00191789Updated Jul 27, 2010Results posted

Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer

A Phase 2 interventional study of gemcitabine and doxorubicin in Breast Cancer, sponsored by Eli Lilly and Company. Completed at 3 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-27.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.

Enrollment
48th of 90
65 · median 68
Started
2003
with 6 others
Phase 2
65 of 95
none open now
Registered
22nd of 95
by date
Lead sponsor
20 of 95
Eli Lilly and Company

Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 48th largest by enrollment of the 90 interventional ones that give a count, is one of 7 that started in 2003, is one of 65 in phase 2, and was the 22nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing gemcitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

Gemcitabine and anthracycline combination has shown encouraging activity as neoadjuvant chemotherapy in locally advanced breast cancer. An addition of sequential gemcitabine and cisplatin, also a highly active combination in this indication, may result in improvement in pathological response and overall survival. Patients with operable breast cancer will be treated in neoadjuvant setting with gemcitabine plus doxorubicin, followed by gemcitabine plus cisplatin.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of breast carcinoma
  • No previous chemotherapy, with bidimensionally measurable locally advanced disease
  • Adequate performance status ( Performance Status [KPS] greater than or equal to 70), bone marrow reserves, hepatic, cardiac and renal functions.

Exclusion criteria

Exclusion Criteria:

  • Inflammatory breast cancer
  • Pregnancy and Breast-feeding
  • Serious concomitant disorder or infection
  • Previous cancer within the last 5 years or a second primary .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Gemcitabine+Doxorubicin+Cisplatin+Surgery

    Gemcitabine: 1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8). Doxorubicin: 60 mg/m\^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m\^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.

    Drug: gemcitabine · Drug: doxorubicin · Drug: cisplatin · Procedure: surgery

Interventions

  • 1200 mg/m\^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m\^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)

    Also known as: LY188011, Gemzar

  • 60 mg/m\^2, IV, every 21 days x 4 cycles (1-4)

  • 70 mg/m\^2, IV, every 21 days x 4 cycles (5-8)

  • Proceduresurgery

    Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)

    Complete pathological response: No invasive tumor cells identified from sections from site of previous cancer. Require evidence corroborating prior presence of invasive cancer, which requires detection of abnormal fibroelastic breast stroma devoid of normal lobular units and contains foamy macrophages with moderate numbers of fibroblasts and mononuclear inflammatory cells. Presence of nondescript collagenised lobules or breast fibrous tissue is not evidence that tumor site has been adequately sampled and macroscopic assessment and sampling is needed until original neoplastic stroma identified.

    Time frame: tumor assessment at baseline and during surgery after eight 21-day treatment cycles

Secondary outcomes

  1. Summary of Deaths During Study

    Time frame: baseline through last cycle on study drug (eight 21-day cycles)

  2. Progression Free Survival (PFS)

    PFS was defined as the date of enrollment to the first date of documented disease progression or death from any cause. Because the median was not reached, results are presented as the Outcome: Number of Participants with Disease Progression or Death at Various Timepoints.

    Time frame: baseline to measured progressive disease or death from any cause (up to 68 months)

  3. Overall Survival

    Overall survival was defined as the date of enrollment to the date of death from any cause. Because the median was not reached, results will be presented as the Outcome: Number of Participants who Died from Any Cause at Various Timepoints.

    Time frame: baseline to date of death from any cause up to 68 months

  4. Time to Treatment Failure

    Time to treatment failure was defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed. Because the upper limit of the 95% Confidence Interval of median survival was not calculable, results are presented as the Outcome: Number of Participants with Time to Treatment Failure at Various Timepoints.

    Time frame: baseline to stopping treatment (up to 68 months)

  5. Number of Patients Eligible for Breast Conservation Surgery at Baseline and Number of Patients Undergoing Breast Conservation Surgery

    The extent and type of surgery was guided by the tumor size, physician and/or patient decision. It was either conservation surgery or mastectomy with axillary lymph node dissection. Results are reported on the number of patients who underwent breast conservation surgery.

    Time frame: baseline, after eight 21-day cycles of study drug

07

Results

Posted Jul 22, 2010

Participant flow

Participant flow — Overall Study
MilestoneGemcitabine+Doxorubicin+Cisplatin+Surgery
Started65
Completed40
Not completed25
Withdrew: Adverse event5
Withdrew: Patient: satisfactory response5
Withdrew: Patient/physician: satisfactory response4
Withdrew: Withdrawal by subject4
Withdrew: Death - possibly study drug related4
Withdrew: Progressive disease/lack of efficacy2
Withdrew: Death - not study-drug related1

Outcome measures

PrimaryNumber of Patients With Pathological Complete Response (Pathological Complete Response Rate)

Complete pathological response: No invasive tumor cells identified from sections from site of previous cancer. Require evidence corroborating prior presence of invasive cancer, which requires detection of abnormal fibroelastic breast stroma devoid of normal lobular units and contains foamy macrophages with moderate numbers of fibroblasts and mononuclear inflammatory cells. Presence of nondescript collagenised lobules or breast fibrous tissue is not evidence that tumor site has been adequately sampled and macroscopic assessment and sampling is needed until original neoplastic stroma identified.

Time frame:
tumor assessment at baseline and during surgery after eight 21-day treatment cycles
Reported as:
Number · participants
Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)
participantsGemcitabine+Doxorubicin+Cisplatin+Surgery
Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)13
SecondarySummary of Deaths During Study
Time frame:
baseline through last cycle on study drug (eight 21-day cycles)
Reported as:
Number · participants
Summary of Deaths During Study
participantsGemcitabine+Doxorubicin+Cisplatin+Surgery
Study Disease0
Study Drug Toxicity: Cardiac arrest1
Study Drug Toxicity: Infection with neutropenia1
Study Drug Toxicity: Neutropenic sepsis2
Myocardial infarction1
SecondaryProgression Free Survival (PFS)

PFS was defined as the date of enrollment to the first date of documented disease progression or death from any cause. Because the median was not reached, results are presented as the Outcome: Number of Participants with Disease Progression or Death at Various Timepoints.

Time frame:
baseline to measured progressive disease or death from any cause (up to 68 months)
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was defined as the date of enrollment to the date of death from any cause. Because the median was not reached, results will be presented as the Outcome: Number of Participants who Died from Any Cause at Various Timepoints.

Time frame:
baseline to date of death from any cause up to 68 months
Reported as:
Median · months

No measurements were reported for this outcome.

SecondaryTime to Treatment Failure

Time to treatment failure was defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed. Because the upper limit of the 95% Confidence Interval of median survival was not calculable, results are presented as the Outcome: Number of Participants with Time to Treatment Failure at Various Timepoints.

Time frame:
baseline to stopping treatment (up to 68 months)
Reported as:
Median · weeks

No measurements were reported for this outcome.

SecondaryNumber of Patients Eligible for Breast Conservation Surgery at Baseline and Number of Patients Undergoing Breast Conservation Surgery

The extent and type of surgery was guided by the tumor size, physician and/or patient decision. It was either conservation surgery or mastectomy with axillary lymph node dissection. Results are reported on the number of patients who underwent breast conservation surgery.

Time frame:
baseline, after eight 21-day cycles of study drug
Reported as:
Number · participiants
Number of Patients Eligible for Breast Conservation Surgery at Baseline and Number of Patients Undergoing Breast Conservation Surgery
participiantsGemcitabine+Doxorubicin+Cisplatin+Surgery
Eligible for Surgery at Baseline0
Underwent Surgery18
Post-hocNumber of Participants With Progressive Disease or Death at Various Time Points Throughout the Study

The cumulative number of participants with an event (either progressive disease or death) are presented at various time points, as well as the number of participants at risk for the event. Participants at risk are the number of participants without progressive disease or still alive at the beginning of each time point.

Time frame:
baseline up to 68 months
Reported as:
Number · participants
Number of Participants With Progressive Disease or Death at Various Time Points Throughout the Study
participantsGemcitabine+Doxorubicin+Cisplatin+Surgery
3 Months: Number of Patients with Event5
3 Months: Number of Patients at Risk59
6 Months: Number of Patients with Event8
6 Months: Number of Patients at Risk50
12 Months: Number of Patients with Event11
12 Months: Number of Patients at Risk41
24 Months: Number of Patients with Event15
24 Months: Number of Patients at Risk36
48 Months: Number of Patients with Event21
48 Months: Number of Patients at Risk23
68 Months: Number of Patients with Event21
68 Months: Number of Patients at Risk1
Post-hocNumber of Participants Who Died From Any Cause at Various Time Points

The cumulative number of participants with an event (death from any cause) are presented at various time points, as well as the number of participants at risk for the event. Participants at risk are the number of participants still alive at the beginning of each time point.

Time frame:
baseline up to 68 months
Reported as:
Number · participants
Number of Participants Who Died From Any Cause at Various Time Points
participantsGemcitabine+Doxorubicin+Cisplatin+Surgery
3 Months: Number of Patients With Event3
3 Months: Number of Patients at Risk60
6 Months: Number of Patients With Event5
6 Months: Number of Patients at Risk51
12 Months: Number of Patients With Event7
12 Months: Number of Patients at Risk43
26 Months: Number of Patients With Event11
26 Months: Number of Patients at Risk37
48 Months: Number of Patients With Event14
48 Months: Number of Patients at Risk24
68 Months: Number of Patients With Event15
68 Months: Number of Patients at Risk1
Post-hocNumber of Participants With Time to Treatment Failure at Various Time Points

This outcome is in place of the time to treatment failure outcome. The cumulative number of participants with an event (disease progression, death as a result of any cause, or early discontinuation of treatment) are presented at various time points, as well as the number of participants at risk for the event. Participants at risk are the number of participants without disease progression, are alive, or did not discontinue treatment early at the beginning of each time point.

Time frame:
baseline to stopping treatment (up to 68 months)
Reported as:
Number · participants
Number of Participants With Time to Treatment Failure at Various Time Points
participantsGemcitabine+Doxorubicin+Cisplatin+Surgery
3 Months: Number of Patients with Event11
3 Months: Number of Patients at Risk59
6 Months: Number of Patients with Event19
6 Months: Number of Patients at Risk50
12 Months: Number of Patients with Event25
12 Months: Number of Patients at Risk41
24 Months: Number of Patients with Event29
24 Months: Number of Patients at Risk36
48 Months: Number of Patients with Event35
48 Months: Number of Patients at Risk23
68 Months: Number of Patients with Event35
68 Months: Number of Patients at Risk1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemcitabine+Doxorubicin+Cisplatin+Surgery—17/65 (26.2%)64/65 (98.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventGemcitabine+Doxorubicin+Cisplatin+Surgery
Neutropenic sepsisInfections and infestations6/65
DiarrhoeaGastrointestinal disorders5/65
Febrile neutropeniaBlood and lymphatic system disorders3/65
NeutropeniaBlood and lymphatic system disorders2/65
Cardiac arrestCardiac disorders2/65
VomitingGastrointestinal disorders2/65
Neutropenic infectionInfections and infestations2/65
PancytopeniaBlood and lymphatic system disorders1/65
ThrombocytopeniaBlood and lymphatic system disorders1/65
Myocardial infarctionCardiac disorders1/65
Most frequent other events
Showing 10 of 24
Most frequent other events
EventGemcitabine+Doxorubicin+Cisplatin+Surgery
AnaemiaBlood and lymphatic system disorders57/65
NeutropeniaBlood and lymphatic system disorders45/65
LeukopeniaBlood and lymphatic system disorders42/65
Aspartate aminotransferase increasedInvestigations27/65
Alanine aminotransferase increasedInvestigations26/65
AlopeciaSkin and subcutaneous tissue disorders26/65
ThrombocytopeniaBlood and lymphatic system disorders17/65
FatigueGeneral disorders15/65
StomatitisGastrointestinal disorders13/65
VomitingGastrointestinal disorders13/65

Baseline characteristics

Age Continuous
Age Continuous(years)Gemcitabine+Doxorubicin+Cisplatin+Surgery
Median46 (31 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Gemcitabine+Doxorubicin+Cisplatin+Surgery
Female65
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Gemcitabine+Doxorubicin+Cisplatin+Surgery
Indian65
Region of Enrollment
Region of Enrollment(participants)Gemcitabine+Doxorubicin+Cisplatin+Surgery
India65
Diagnosis
Diagnosis(participants)Gemcitabine+Doxorubicin+Cisplatin+Surgery
Histopathological12
Cytological53
Disease Stage
Disease Stage(participants)Gemcitabine+Doxorubicin+Cisplatin+Surgery
Stage IIA3
Stage IIB30
Stage IIIA18
Stage IIIB14
Hormone Receptor Status
Hormone Receptor Status(participants)Gemcitabine+Doxorubicin+Cisplatin+Surgery
ER+ / PR+27
ER+ / PR-8
ER- / PR+3
ER- / PR-25
No Assessment2
Human Epidermal Growth Factor Receptor 2 (HER-2) Status
Human Epidermal Growth Factor Receptor 2 (HER-2) Status(participants)Gemcitabine+Doxorubicin+Cisplatin+Surgery
027
1+8
2+2
3+19
Not Detected7
Insufficient Sample2

6 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician.
    Pune, Maharashtra 411001, India
  • For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician.
    Vellore, Tamil Nadu 632004, India
  • For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician.
    Delhi, 110029, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Feb 2003
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Jul 22, 2010
Last update
Jul 27, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00191789
First posted
Sep 19, 2005
Start date
Feb 2003
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Jul 22, 2010
Last update
Jul 27, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM - 5PM Eastern Time (UTC/GMT -5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Doxorubicin · Cisplatin

Start the discussion